Tütün Kullanım Bozuklukluklarının Psikofarmakolojisi
Özet
Dünya nüfusunun önemli bir kısmı sigara kullanmaya devam etmekte olup sigaranın kırk yaşından önce bırakılması ölümleri yüzde doksan oranında azaltabilmektedir. Bu süreçte uzman danışmanlığı ile desteklenen ilaç tedavileri başarı şansını ciddi şekilde artırmaktadır. Sigara bırakma tedavisinde birinci seçenek olarak vareniklin, bupropion ve nikotin yerine koyma tedavisi (NRT) tercih edilmektedir. Vareniklin, nikotinik reseptörlere parsiyel agonist olarak bağlanıp aşerme ve yoksunluğu en etkili şekilde azaltan monoterapidir. Bir dopamin-norepinefrin geri alım inhibitörü antidepresan olan bupropion, nikotinin ödül yolaklarını baskılayarak etki gösterir ve özellikle epileptik nöbet riski taşıyanlarda kontrendikedir. En yaygın yöntem olan NRT; bant, sakız ve pastil gibi formlarla kandaki nikotin düzeyini yavaşça dengeleyerek yoksunluğu önler ve kombinasyon halinde kullanımı başarıyı artırır. İkinci seçenek tedaviler arasında trisiklik antidepresan nortiriptilin ve yan etkileri nedeniyle kullanımı sınırlı olan klonidin yer almaktadır. Henüz FDA onayı bulunmayan bitkisel kaynaklı cytisine reseptör agonisti olarak aşermeyi azaltırken, elektronik sigaralar ise kısa vadeli bir seçenek olarak görülse de kalıcı bağımlılık riski taşımaktadır. Sonuç olarak, sigarayı bırakmada farmakoterapinin bireysel danışmanlıkla desteklenmesi kalıcı başarı oranını en üst seviyeye çıkarmaktadır.
Although a significant portion of the global population continues to smoke, quitting before the age of forty can reduce smoking-related mortality by up to ninety percent. During this process, pharmacological treatments supported by expert counseling substantially increase the chances of success. Varenicline, bupropion, and nicotine replacement therapy (NRT) are preferred as first-line treatments for smoking cessation. Varenicline is the most effective monotherapy, binding to nicotinic receptors as a partial agonist to efficiently reduce cravings and withdrawal symptoms. Bupropion, a dopamine-norepinephrine reuptake inhibitor antidepressant, works by suppressing the reward pathways of nicotine and is particularly contraindicated in individuals at risk for epileptic seizures. NRT, the most common method, manages withdrawal by gradually stabilizing blood nicotine levels through forms such as patches, gums, and lozenges, and its combination use enhances success. Second-line treatments include the tricyclic antidepressant nortriptyline and clonidine, whose clinical use is limited due to dose-dependent adverse effects. Cytisine, a plant-derived receptor agonist that lacks FDA approval, reduces cravings, while electronic cigarettes are considered a second-line option but carry a risk of permanent nicotine dependence. Consequently, combining pharmacotherapy with individualized behavioral counseling maximizes the long-term success rate of smoking cessation.
Referanslar
Dai X, Gakidou E, Lopez AD. Evolution of the global smoking epidemic over the past half century: Strengthening the evidence base for policy action. Tob Control. 2022;31(2):129–37.
Jha P, Ramasundarahettige C, Landsman V, Rostron B, Thun M, Anderson RN, et al. 21st-Century Hazards of Smoking and Benefits of Cessation in the United States. New England Journal of Medicine. 2013 Jan 24;368(4):341–50.
Pezzuto A, Carico E. Effectiveness of smoking cessation in smokers with COPD and nocturnal oxygen desaturation: Functional analysis. Clinical Respiratory Journal. 2020 Jan 1;14(1):29–34.
Elrashidi MY, Ebbert JO. Emerging drugs for the treatment of tobacco dependence: 2014 update. Vol. 19, Expert Opinion on Emerging Drugs. Informa Healthcare; 2014. p. 243–60.
Kotz D, Brown J, West R. “Real-world” effectiveness of smoking cessation treatments: A population study. Addiction. 2014 Mar;109(3):491–9.
Thomas KH, Dalili MN, López-López JA, Keeney E, Phillippo DM, Munafò MR, et al. Comparative clinical effectiveness and safety of tobacco cessation pharmacotherapies and electronic cigarettes: a systematic review and network meta-analysis of randomized controlled trials. Vol. 117, Addiction. John Wiley and Sons Inc; 2022. p. 861–76.
Gómez-Coronado N, Walker AJ, Berk M, Dodd S. Current and Emerging Pharmacotherapies for Cessation of Tobacco Smoking. Vol. 38, Pharmacotherapy. Pharmacotherapy Publications Inc.; 2018. p. 235–58.
Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: An overview and network meta-analysis. Vol. 2013, Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd; 2013.
Giulietti F, Filipponi A, Rosettani G, Giordano P, Iacoacci C, Spannella F, et al. Pharmacological Approach to Smoking Cessation: An Updated Review for Daily Clinical Practice. Vol. 27, High Blood Pressure and Cardiovascular Prevention. Adis; 2020. p. 349–62.
Mendelsohn C. Optimal use of smoking cessation pharmacotherapy. Aust Prescr. 2022 Feb 1;45(1):10–4.
Stahl SM. Sthal’nın Temel Psikofarmakolojisi Reçete Kılavuzu . 5th ed. Uzbay Tayfun İ, editor. İstanbul: İstanbul Tıp Kitabevleri; 2017. 788 p.
Chang PH, Chiang CH, Ho WC, Wu PZ, Tsai JS, Guo FR. Combination therapy of varenicline with nicotine replacement therapy is better than varenicline alone: A systematic review and meta-analysis of randomized controlled trials. BMC Public Health. 2015 Jul 22;15(1).
Rollema H, Hurst RS. The contribution of agonist and antagonist activities of α4β2* nAChR ligands to smoking cessation efficacy: a quantitative analysis of literature data. Vol. 235, Psychopharmacology. Springer Verlag; 2018. p. 2479–505.
Robinson JD KHMKGBDBJCYGRTJCPCP. Bupropion XL and SR have similar effectiveness and adverse event profiles when used to treat smoking among patients at a comprehensive cancer center. Am J Addict. 2022 May;31(3):236–41.
Swan GE, McAfee T, Curry SJ, Jack LM, Javitz H, Dacey S, et al. Effectiveness of bupropion sustained release for smoking cessation in a health care setting: a randomized trial. Arch Intern Med. 2003 Oct 27;163(19):2337–44.
Stahl SM. Stahl’ın Temel Psikofarmakolojisi Reçete Klavuzu. 5th ed. Uzbay Tİ, editor. İstanbul: İstanbul Tıp Kitabevleri; 2017. 104 p.
Benowitz NL, Pipe A, West R, Hays JT, Tonstad S, McRae T, et al. Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial. JAMA Intern Med. 2018;178(5):622–31.
Lindson N, Chepkin SC, Ye W, Fanshawe TR, Bullen C, Hartmann-Boyce J. Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. Vol. 2019, Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd; 2019.
Devi R, Barman D, Sinha S, Hazarika S, Das S. Nicotine replacement therapy: A friend or foe. J Family Med Prim Care. 2020;9(6):2615.
Niaura R, Sayette M, Shiffman S, Glover ED, Nides M, Shelanski M, et al. Comparative efficacy of rapid-release nicotine gum versus nicotine polacrilex gum in relieving smoking cue-provoked craving. Addiction. 2005 Nov;100(11):1720–30.
Henningfield JE, Fant R v, August ;, Buchhalter R, Stitzer ML. Pharmacotherapy for Nicotine Dependence 1 [Internet]. Available from: http://CAonline.AmCancerSoc.org
Mendelsohn CP. Optimising nicotine replacement therapy in clinical practice. Aust Fam Physician. 2013 May;42(5).
Henningfield JE, Radzius A, Cooper TM, Clayton RR. Drinking coffee and carbonated beverages blocks absorption of nicotine from nicotine polacrilex gum. JAMA. 1990 Sep 26;264(12):1560–4.
Royal Australian College of General Practitioners. Chapter 2. Pharmacotherapy for smoking cessation. In: 30.09.22 tarihinde https://www.racgp.org.au/getattachment/c07241b0-9dc1-41bd-b25b-764389a675c9/Pharmacotherapy-for-smoking-cessation.aspx. adresinden ulaşılmıştır., editor. Supporting smoking cessation: a guide for health professionals . 2020.
Ferguson SG, Schüz B, Gitchell JG. Use of smoking cessation aids: Role of perceived safety and efficacy. Vol. 7, Journal of Smoking Cessation. Cambridge University Press; 2012. p. 1–3.
Hughes JR, Stead LF, Lancaster T. Nortriptyline for smoking cessation: a review. Nicotine Tob Res. 2005 Aug;7(4):491–9.
Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD000031.
Gómez-Coronado N, Walker AJ, Berk M, Dodd S. Current and Emerging Pharmacotherapies for Cessation of Tobacco Smoking. Vol. 38, Pharmacotherapy. Pharmacotherapy Publications Inc.; 2018. p. 235–58.
Gourlay SG, Stead LF, Benowitz N. Clonidine for smoking cessation. Vol. 2017, Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd; 2004.
Tutka P, Vinnikov D, Courtney RJ, Benowitz NL. Cytisine for nicotine addiction treatment: a review of pharmacology, therapeutics and an update of clinical trial evidence for smoking cessation. Addiction. 2019 Nov 1;114(11):1951–69.
European Network for Smoking and Tobacco Prevention aisbl (ENSP. AVRUPA SiGARA BIRAKMA KILAVUZU [Internet]. Karalezli A, Börekçi Ş, editors. 2012. Available from: www.ensp.org
Musshoff F, Madea B. Fatal cytisine intoxication and analysis of biological samples with LC-MS/MS. Forensic Sci Int. 2009 Apr 15;186(1–3):e1-4.
Hanewinkel R, Niederberger K, Pedersen A, Unger JB, Galimov A. E-cigarettes and nicotine abstinence: a meta-analysis of randomised controlled trials. Vol. 31, European Respiratory Review. European Respiratory Society; 2022.
